With kidney disease being one of the top 10 leading causes of death in the U.S., our focus at ISPOR—The Professional Society for Health Economics and Outcomes Research’s annual meeting this year will be on nephrotic syndrome outcomes. Check out our poster sessions. #ISPORannual
Mallinckrodt Pharmaceuticals
Pharmaceutical Manufacturing
Listening for Needs, Delivering Solutions
About us
At Mallinckrodt, we use strategic vision and employee-driven momentum to pursue a powerful mission: Listening for needs and delivering solutions. As a leader in specialty pharmaceuticals, we develop, manufacture, market and distribute innovative treatments for underserved patient populations within neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes and gastrointestinal products. . Our expertise also extends into acute and critical care hospital products, as well as our broad portfolio of generic prescription medicines and active pharmaceutical ingredients. Together, we’re helping shape the future of the specialty pharmaceuticals industry by leveraging the values our founders instilled over 155 years ago – quality, integrity and service. To learn more about Mallinckrodt, visit www.mallinckrodt.com. Equal Opportunity Employer Mallinckrodt Pharmaceuticals provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity, national origin, age, disability, veteran status or genetics. In addition to federal law requirements, Mallinckrodt Pharmaceuticals complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation and training.
- Website
-
http://www.mnk.com
External link for Mallinckrodt Pharmaceuticals
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1,001-5,000 employees
- Headquarters
- Dublin, Ireland
- Type
- Public Company
- Founded
- 1867
- Specialties
- Specialty Pharmaceuticals, Active Pharmaceutical Ingredients, Specialty Generics, Pain Medications, Autoimmune and Rare Diseases, Neonatal Respiratory Critical Care, Hemostasis Products, and Extracorporeal Photopheresis
Locations
-
Primary
Get directions
College Business & Technology Park
Dublin, Ireland, IE
-
Get directions
3 Lotus Park
The Causway
Staines-Upon-Thames , Surrey TW18 3AG, GB
-
Get directions
440 Route 22 East
Bridgewater, NJ 08807, US
-
Get directions
675 James S. McDonnell Blvd
Hazelwood, MO 63042, US
Employees at Mallinckrodt Pharmaceuticals
Updates
-
Our team will be unveiling our brand new interactive exhibit at the 2024 Annual Pediatric Academic Societies Meeting showcasing our full line of delivery systems for neonates in the #NICU and their #HealthcareProfessionals in the U.S., including our recently FDA-cleared, next-generation delivery system. Attending #PAS2024? Stop by booth #301 to learn more
-
-
As we celebrate Earth Day, we reflect on the importance of environmental conservation and our role in building a sustainable future. At Mallinckrodt, we are committed to minimizing our global environmental footprint and contributing positively to the planet's well-being. See our sustainability report here https://lnkd.in/eUg--Wb4
-
-
Proud to support the Cutaneous Lymphoma Foundation in celebrating 25 years of serving the cutaneous lymphoma community! Come and meet our patient ambassador and find out more. #CLF #25Years
-
We are pleased to be sponsors of the 5th World Congress of Cutaneous Lymphomas and look forward to attending. #5WCCL
-
-
April is National Minority Health Month, a time to raise awareness and take action to improve the health of racial and ethnic minorities and other underserved groups. At Mallinckrodt, we understand the importance of cultural diversity in promoting health equity. It's essential to provide healthcare solutions for all patients.
-
-
Best of luck to the MNK International Team (Dr. Oscar Alejandro Mesa Zapata (He/him/his), Karin Wilkenson, Erika Ödlund, Patricia Claris, Christof Aust, Daiane Devecchi, Stefan Bauer) running the London Landmarks Half Marathon in support of Anthony Nolan. Anthony Nolan is a charity that supports people with blood cancers by helping them find a stem cell donor.
-
-
Our team will be at the American Society of Cataract and Refractive Surgery (ASCRS)’s Annual Meeting to connect with attendees on #Ophthalmology treatment options for their patients. Visit us at booth #348 to learn more on how we’re listening for needs and delivering solutions. #ASCRS2024
-
-
April is #SarcoidosisAwarenessMonth. By publishing real-world data (#RWD) on health and treatment outcomes for sarcoidosis patients, Mallinckrodt remains committed to recognizing and addressing the health disparities in symptomatic sarcoidosis care and helping to support the needs of appropriate patients. Read more about our findings in Taylor & Francis Group’s Therapeutics and Clinical Risk Management here: https://bit.ly/3vmLf2W
-